The EAL is seeking RDNs and NDTRs who work with patients, clients, or the public to treat children and adolescents living with type 1 diabetes, for participation in a usability test and focus group. Interested participants should email a professional resume to by July 15, 2024.

MNT: Glycemic Outcomes (2022)

Author and Year:
Cohen L, Taveira T, et al. 2011
PubMed ID:
Article Title:
Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes.
Cohen L, Taveira T, Khatana S, Dooley A, Pirraglia P, Wu W
The Diabetes Educator
Year of publication:
Page numbers:
Study Design:
Randomized Controlled Trial
Risk of Bias Assessment Rating:
Some concerns
Inclusion Criteria:
Participants were eligible for the study on the basis of the following criteria: diagnosis of type 2 diabetes; A1C > 7.0%, LDL > 100 mg/dL (2.59 mmol/L) or LDL > 70 mg/dL (1.81 mmol/L) for those with coronary artery disease, and blood pressure > 130/80 mm Hg, each documented at least once in the medical records in the 6 months before enrollment; and willingness to participate and discuss diabetes and cardiac risk factors in a group setting and provide written informed consent
Exclusion Criteria:
Patients were excluded on the basis of the following criteria: having gestational diabetes mellitus; unable to attend the group sessions for reasons such as lack of transportation, psychiatric instability (actively suicidal, psychotic), or organic brain injury that precluded them from diabetes self-care
Research Purpose:
To assess whether VA MEDIC-E (Veterans Affairs Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction[EM DASH] Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention.
Blinding efforts:
No blinding efforts were included or discussed in the manuscript
Study Location:
Kingston, RI
Source(s) of Funding:
Please specify names of funders:
The Sandra A. Daugherty Foundation (principal investigator, Dr Wu)